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aBstRact  Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) 
remodeling and metastatic progression, the main cause of cancer-associated death. 
We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed 
in tumor-infi ltrating TAMs and that its genetic ablation signifi cantly impairs lung metastasis forma-
tion. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin 
recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2 + macrophages 
escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the tran-
scription factor YAP. In human lobular breast and gastric carcinomas, DAB2 + TAMs correlated with 
a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratifi cation of 
patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs. 
 SIGnIFICAnCE:  DAB2 expression in macrophages is essential for metastasis formation but not primary 
tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, 
which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of 
DAB2 + TAMs in patients with cancer correlates with worse prognosis. 
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 intRoDuction 
 Because metastases are estimated to be responsible for 
about 90% of cancer-related deaths worldwide, there is an 
urgent need to understand the mechanisms underlying the 
metastatic process and identify therapeutic targets and bio-
markers of metastatic disease ( 1 ). In solid cancers, tumor-
associated macrophages (TAM) are abundant immune cells, 
and their presence correlates with a poor prognosis ( 2–5 ). 
TAMs exhibit tumor-supporting actions both at primary 
(i.e., cell invasion and intravasation) and metastatic sites (i.e., 
extravasation, seeding, and cell growth; refs.  6, 7 ). Differ-
ent molecules infl uence the macrophage-assisted metastatic 
process, such as colony-stimulating factor 1 (CSF1; ref.  8 ) 
and CCL2 ( 6 ), which are mainly responsible for TAM and 
metastasis-associated macrophage (MAM) accumulation; 
however, the lack of either specifi c markers or molecularly 
defi ned mechanisms responsible for TAM-mediated metasta-
sis promotion remains a limiting factor for the development 
of antimetastatic therapies ( 9 ). 
 Disabled homolog 2, mitogen-responsive phosphoprotein 
(DAB2) exists as two isoforms (96 or 67 kDa following post-
translational modifi cation) and is a phosphoprotein with 
an actin-binding  N -terminal domain, a central conserved 
domain, and a proline/serine-rich  C -terminal portion with 
binding sites for SH3 domains. DAB2 was initially identifi ed 
in a CSF1-responsive macrophage cell line ( 10 ). Recent stud-
ies have suggested that DAB2 modulates cancer-associated 
RAS–MAPK ( 11 ), TGF β ( 12 ), NF κ B ( 13 ), and WNT ( 14 ) sig-
naling. DAB2 is thought to act as an adaptor protein between 
cell membrane receptors and the machinery responsible 
for the clathrin-mediated endocytosis (CME) of membrane 
receptors ( 15, 16 ). Combining endocytosis with directional 
exocytosis, DAB2 concentrates shuttling proteins into spe-
cifi c sites of the cell membrane, favoring interplay with the 
surrounding extracellular matrix (ECM; ref.  17 ). Changes in 
ECM composition, tissue stiffness, and integrin repertoire 
govern cell directional migration in response to gradients of 
adhesive molecules and matrix rigidity, migratory processes 
known as haptotaxis and durotaxis, respectively ( 18 ). 
 The mechanisms that control ECM remodeling and cellular 
movement during metastatic invasion are ill-defi ned, primar-
ily because information about specifi c molecular interactions 
among cells and matrix in the context of macrophage-assisted 
metastasis is missing. Here we unveil a fundamental and nonre-
dundant prometastatic activity of DAB2 in TAMs. Moreover, we 
demonstrate the value of the gene encoding DAB2 as a potential 
prognostic marker for disease progression in patients, either as a 
single gene or in association with other tumor-promoting genes. 
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Results
Myeloid Cells Expressing Dab2 Display  
Protumoral Features
Previous gene chip data obtained by our group on tumor-
infiltrating myeloid cells isolated from different mouse tumors 
highlighted Dab2 as one of the most upregulated genes. To 
define DAB2 expression in the tumor microenvironment 
(TME) and begin dissecting the effects of Dab2 deletion in mye-
loid cells, we generated an autochthonous transgenic mouse 
model of lobular breast carcinoma, the PyMT-Dab2flox/flox; 
Tie2-Cre+ (referred as PyMT-Dab2 KO) strain, lacking the 
DAB2 protein in the entire hematopoietic lineage and a frac-
tion of endothelial cells (19). A single-cell RNA-sequencing 
analysis (scRNA-seq) was performed on FACS-sorted, tumor-
infiltrating myeloid cells from either PyMT-Dab2 KO mice 
or their littermates [PyMT-wild type (WT)]. A total of 5,170 
myeloid cells were grouped into 14 different clusters that we 
define as six macrophage clusters (MΦ_1-6); two monocyte 
clusters, Mono_1 (Ly6c2+Ccr2+ inflammatory monocytes, 
iMo) and Mono_2 (mix of iMo and Cebpb+Nr4a1+ patrolling 
monocytes, pMo); four dendritic cell (DC) clusters (Cd209a+ 
DC_1, Ccr7− DC_2, Cd24a+ DC_3 and Ccr7+ DC_4); a mixed 
cluster of macrophages and DCs (MΦ-DC); and a cluster of 
PMN-like cells, which did not express the canonical neutro-
phil marker (i.e., Ly6g; Fig. 1A; Supplementary Fig. S1A and 
S1B; Supplementary Data S1). Dab2 was present in almost all 
clusters of macrophages, in inflammatory Mono_1 class, in 
MΦ-DC cells, and in 2 of 4 clusters of DCs (DC_1 and DC_2; 
Supplementary Fig.  S1C). Moreover, Dab2 KO cells were 
strongly enriched in MΦ_4 and weakly enriched in MΦ_1 
and MΦ_5, whereas WT cells were mainly represented in the 
MΦ_2 cluster (Supplementary Fig.  S1D). We then analyzed 
the genes differentially expressed between all macrophages 
from WT compared with Dab2 KO mice (Fig.  1B). Among 
those upregulated in WT cells, we found genes involved in 
tissue remodeling (Cxcl2, Mmp12) and promotion of M2-like 
phenotype (Atf3, Fos, Jun, Klf4; refs. 20–23). On the contrary, 
Dab2 KO cells displayed an increased expression of IFN-
inducible genes (Ly6e, Ccl5, Iftm3, Ifi27l2a, Irf7). To outline 
distinct macrophage states, we performed an unsupervised 
clustering of either WT (n = 1,682 cells) or Dab2 KO (n = 
1749 cells) macrophages separately. We identified 6 clusters 
of macrophages in WT (all expressing Dab2, Supplemen-
tary Fig.  S1E) and 7 in Dab2 KO tumors (Fig.  1C and D). 
On the basis of the expression levels of genes distinctive 
of each cluster, we classified clusters as low inflammatory 
(MΦ_WT0, MΦ_WT1, MΦ_WT5, MΦ_KO0, MΦ_KO1, MΦ_
KO5, MΦ_KO6), mixed inflammatory (MΦ_WT2, MΦ_WT3, 
MΦ_KO3), and proinflammatory (MΦ_WT4, MΦ_KO2, 
MΦ_KO4) clusters (Fig.  1C and D; Supplementary Data 
S2 and S3). However, several macrophage-related processes 
(i.e., antigen-presenting, metabolism, heat shock response, 
protumoral, and others) were identified and annotated in 
Supplementary Data S3. Two clusters were shared by WT 
and KO tumors (WT2-KO3 mixed-inflammatory and WT4-
KO4 IFN signature), whereas others designated only one 
condition, such as the antigen-presenting cluster in KO mice 
(MΦ_KO0) and the protumoral MΦ_WT5 cluster character-
ized by a Ccl7, Ccl8, and Mrc1 gene signature (Fig. 1C and D). 
To explore relationships between clusters, we calculated theo-
retical trajectories for WT and Dab2 KO macrophages based 
on a minimal spanning tree on the clusters. Three prospec-
tive trajectories were identified for WT macrophages, each 
starting from inflammatory low–mixed clusters (MΦ_WT1, 
MΦ_WT2, MΦ_WT3) and leading to two poorly inflamma-
tory terminal branches, MΦ_WT0 (inflammatory inactive) 
and MΦ_WT5 (protumoral signature), as well as to one char-
acterized by interferon signature (MΦ_WT4; Supplementary 
Fig. S1F; Supplementary Data S3). On the contrary, Dab2 KO 
trajectory presented a common path starting with cells with 
a low/anti-inflammatory profile (MΦ_KO6 and MΦ_KO5) 
and reaching either strong interferon response profile (MΦ_
KO4) or highly inflammatory macrophage terminal branches 
(MΦ_KO2; Supplementary Fig.  S1F; Supplementary Data 
S3). Collectively, these data support the existence of unique 
functional states for WT and Dab2 KO macrophages.
Myeloid Cells Expressing DAB2 Support the 
Metastatic Process by a Mechanism Independent 
from the Adaptive Immune Response
To assess the contribution of DAB2-expressing myeloid 
cells in tumor progression and metastatic spread, we ortho-
topically injected the MN-MCA1 fibrosarcoma cell line in 
WT and Dab2 KO mice. Dab2 KO mice showed a significant 
reduction in the number of lung metastases when compared 
with WT mice (Fig. 2A and B). On the contrary, there was no 
significant alteration in the primary tumor growth (Fig. 2C). 
Metastasis reduction in Dab2 KO mice challenged with MN-
MCA1 tumor cells was confirmed in the Dab2flox/flox;LysMCre+ 
mouse strain, which targets gene deletion in monocytes/mac-
rophages and neutrophils (24), further consolidating the role 
of DAB2+ myeloid cells in metastatic cascade (Fig. 2D–F). We 
then tested the outcome of Dab2 deficiency in breast cancer 
models metastasizing to the lung. WT mice, orthotopically 
injected with syngeneic E0771 cells, presented lung metastatic 
foci compared with an almost complete absence of lesions in 
Dab2 KO mice (Fig.  2G and H), with a slight alteration in 
primary tumor growth (Fig. 2I). Similarly, in PyMT-Dab2 KO, 
we found a reduction in metastasis number, area, and burden 
compared with their control littermates (PyMT-WT; Fig.  2J 
and K; Supplementary Fig.  S2A and S2B), whereas primary 
tumor growth and tumor onset were unaltered (Fig. 2L; Sup-
plementary Fig.  S2C). Dab2 deficiency did not induce any 
obvious alteration either in the immune-suppressive activity 
of myeloid cells as well as in the recruitment of immune cell 
subpopulations to the tumor mass (Supplementary Fig. S2D 
and S2E). Moreover, we better characterized T and natural 
killer (NK) cells in MN-MCA1 tumor-bearing mice. We did 
not detect any difference in the percentage of CD4+ T, CD8+ 
T, and NK cells infiltrating the primary tumors of WT and 
Dab2 KO mice (Supplementary Fig. S2F), as well as in IFNγ 
and granzyme (GRZ) B expression in tumor-infiltrating CD8+ 
T and NK cells after a 4-hour stimulation with PMA and 
iomomycin (Supplementary Fig. S2G). Actually, we observed 
a slightly higher presence of CD4+IFNγ+ cells in Dab2 KO 
mice compared with WT mice (Supplementary Fig.  S2G, 
left). Collectively, our results argue that tumor-infiltrating 
myeloid cells expressing DAB2 are responsible for tumor cell 
invasiveness by a mechanism independent of the immune 
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Figure 1.  scRNA-seq analysis of tumor-infiltrating myeloid cells. A, tSNE visualization of 5,170 cells. WT and Dab2 KO cells were clustered together. 
B, Heat map of differentially expressed genes between WT and Dab2 KO MΦs. C and D, tSNE analysis of macrophages from WT (C) and Dab2 KO (D) mice. 






















































































































suppression of adaptive antitumor immune response against 
the primary tumor.
DAB2 Is Mainly Expressed by TAMs Localized 
along the Invasive Tumor Border
Our scRNA-seq experiment suggested that Dab2 expression 
was enriched in several macrophage populations. Therefore, 
we evaluated the expression of DAB2 protein among different 
tumor-infiltrating myeloid cells using a highly specific anti-
DAB2 antibody. As expected, DAB2 isoforms were detected 
in TAMs isolated from MN-MCA1 tumor–bearing mice, to 
a much lower extent in monocytes and completely absent 
in granulocytes (Fig.  3A; Supplementary Fig.  S3A, top, and 
S3B). Moreover, DAB2 was expressed in TAMs sorted from 
PyMT primary tumors, but not in resident mammary tissue 
macrophages (MTM; Fig.  3B; Supplementary Fig.  S3A, bot-
tom). Within both MN-MCA1 and PyMT-WT tumors, DAB2+ 
TAMs were mainly localized in perilesional areas at the 
invasive front line between the tumor and the surrounding 
healthy tissue, with fewer numbers in the tumor core as well 
as in both healthy muscle and normal breast (Fig. 3C; Supple-
mentary Fig. S3C and S3D). The differentiation and prolifer-
ation of monocytes and macrophages is mainly controlled by 
CSF1 and CSF2 cytokines (25). Because both transplantable 
tumor cell lines secreted CSF1 (Fig. 3D), we investigated the 
effects of this cytokine on Dab2 gene expression. Bone mar-
row (BM)–derived CD11b+ cells isolated from either tumor-
bearing or tumor-free mice upregulated Dab2 mRNA when 
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Figure 2.  Dab2 deficiency in myeloid cells affects the metastatic process. A, Representative hematoxylin and eosin (H&E)-stained microscopy images 
of the lung metastasis in either WT or Tie2-Cre Dab2 KO mice orthotopically injected with MN-MCA1 fibrosarcoma cells. Scale bar, 800 μm. B, Quanti-
fication of lung metastases number. C, Primary tumor growth reported as tumor weight (g) and measured 24 days after tumor challenge. WT (n = 20) or 
Tie2-Cre Dab2 KO (n = 17), pooled from three independent experiments. D, Representative H&E-stained microscopy images of the lung metastases in 
either LySM-Cre Dab2 KO mice or their littermates, orthotopically injected with MN-MCA1 fibrosarcoma cells. Scale bar, 800 μm. E, Quantification of 
lung metastasis number. F, Primary tumor growth reported as tumor weight (g) and measured 24 days after tumor challenge. WT (n = 11) or Dab2 KO (n = 
9), pooled from two independent experiments. G, Representative H&E-stained microscopy images of the lung metastases in either WT or Tie2-Cre Dab2 
KO mice orthotopically injected with E0771 breast cancer cells. Scale bar, 800 μm. H and I, Number of lung metastases (H) and primary tumor growth over 
time (I) are reported. WT (n = 22) and Dab2 KO mice (n = 18), pooled from three independent experiments. J, Representative H&E-stained microscopy 
images of the lung metastases in either WT or Tie2-Cre Dab2 KO PyMT transgenic mice. Scale bar, 800 μm. K, Quantification of lung metastasis numbers 
by H&E staining of PyMT-WT (n = 13) or PyMT-Dab2 KO (n = 12) mice. L, Tumor growth reported as tumor volume (mm3) evaluated over time. Data are 
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exposed to either CSF1 or E0771 tumor cell supernatant 
but not in direct coculture with the tumor cells (Fig.  3E). 
The amounts of Dab2 mRNAs were significantly higher when 
CD11b+ cells were isolated from tumor-bearing mice (Fig. 3E). 
Accordingly, p96 and p67 DAB2 isoforms were increased dur-
ing the CSF1-driven in vitro macrophage differentiation from 
BM precursors (Fig.  3F). Dab2 genetic ablation in CD11b+ 
cells did not alter macrophage differentiation and expansion 
(Supplementary Fig. S3E), indicating that Dab2 is not overtly 
involved in CSF1-dependent signal transduction. Moreover, 
Dab2 transcription was also induced by CSF1 in mature mac-
rophages isolated from MN-MCA1 tumors (Fig. 3G).
Because in vitro cultures generate adherent macrophages, 
we addressed the interplay between cytokines and mechanical 
cues during in vitro differentiation by treating BM precur-
sors under adherent or suspension culture conditions. Dab2 
mRNA upregulation induced by CSF1 and tumor-derived 
soluble factors was impaired when cells were not anchored to 
a solid, stiff surface (i.e., plastic), indicating that chemical and 
mechanical stimuli must be integrated for a full induction of 
Dab2 gene in macrophages (Fig. 3H).
Integrin Recycling and ECM Remodeling Mediated 
by DAB2 Macrophages Promote Tumor Cell Invasion
Considering that DAB2+ macrophages were localized at 
the tumor-invasive front, we investigated their direct par-
ticipation in tumor cell spreading. E0771 breast cancer cells 
cocultured with WT TAMs displayed an increased invasive 
ability within the surrounding matrix when compared with 
either E0771 cells alone or cocultured with Dab2-deficient 
TAMs (Fig. 4A).
In cancer cells, DAB2 can regulate the internalization and 
recycling of different membrane proteins, including integrins 
(26), which mediate cell–ECM component interactions. To 
verify whether DAB2 could be involved in integrin recycling 
in macrophages, we evaluated the surface expression of three 
integrin heterodimers, α1β1, α5β1, and α6β1, which bind 
collagen, fibronectin, and laminin, respectively. We found 
that the lack of DAB2 in bone marrow–derived macrophages 
(BMDM) influenced α5, α6, β1, but not α1 integrin turnover, 
leading to their accumulation on the plasma membrane 
without affecting the levels of total protein and mRNA 
(Fig.  4B and C; Supplementary Fig.  S4A). Because integrins 
are key regulators of diverse cell movement types (27), we 
examined the ability of DAB2+ macrophages to migrate in 
response to either soluble (chemotactic) or matrix-bound 
(haptotactic) cues. WT or Dab2 KO BMDMs exhibited a 
comparable directional movement toward chemokine gradi-
ents (Supplementary Fig. S4B), but were defective in moving 
through the 3-D Matrigel substrate when lacking Dab2 (Sup-
plementary Fig. S4C), consistent with a defect in haptotaxis, 
but not chemotaxis. The altered integrin surface distribution 
in Dab2 KO BMDMs also impaired their ability to internalize 
ECM fragments (Fig. 4D), a process occurring during matrix 
Figure 3.  Tumor microenvironment induces DAB2 expression in TAMs that localize along tumor borders. A and B, Western blot analysis for DAB2 
expression (p96 and p67 isoforms) on FACS-sorted myeloid cell subsets (granulocytes, monocytes, and TAMs) infiltrating primary tumors from either 
MN-MCA1-tumor bearing mice (A) or TAMs and MTMs from PyMT mice (B). C, Quantification of DAB2+ TAMs on total TAMs evaluated on High Power Field 
(HPF) images from different areas of either MN-MCA1 (left) or PyMT tumors (right). D, Secretion of CSF1 and CSF2 assessed by ELISA in cancer cell 
supernatant (n = 2 independent experiments). E, Dab2 expression assessed by qRT-PCR on CD11b+ cells isolated from BM of tumor-free and MN-MCA1-
bearing mice and cultured for 24 hours in the presence of CSF1, E0771 supernatant, or E0771 cells (n = 3 independent experiments). F, DAB2 expression 
evaluated by Western blot analysis on BM precursors from WT mice during differentiation with CSF1. G, Dab2 expression assessed by qRT-PCR on TAMs 
isolated from MN-MCA1 tumor–bearing mice, cultured for 24 hours in the absence (UT) or presence of CSF1 (n = 3 independent experiments). H, Dab2 
expression assessed by qRT-PCR on CD11b+ cells isolated from BM of tumor-free mice and cultured for 6 hours either as adherent cells or in suspension, 
in the presence of CSF1 or supernatant of E0771 cells (n = 3 independent experiments). A, B, and F, Actin was used as loading control. Data are presented 
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remodeling (28). Accordingly, the ability of E0771 cells to 
invade the previously macrophage-remodeled Matrigel was 
compromised (Supplementary Fig.  S4D), highlighting that 
tumor cell invasion relies on matrix reorganization through 
a DAB2-dependent step in macrophages. Furthermore, a sec-
ond harmonic generation (SHG) analysis of primary explants 
of MN-MCA1 tumors confirmed that the ECM presented an 
organized and dense structure in tumors grown in Dab2 KO 
mice compared with WT controls (Fig. 4E and F). Therefore, 
we conclude that Dab2 KO macrophages have an impaired 
endocytosis of ECM proteins due to an altered integrin turnover, 
which affects the macrophage tissue-remodeling properties.
DAB2+ Macrophages Favor Tumor Cell Invasion 
through Integrin–ECM Interaction
To dissect further the role of DAB2 in integrin-mediated 
remodeling of ECM, we generated different CRISPR/Cas9 
clones of RAW 264.7 macrophage cell line by deleting either 
Figure 4.  DAB2 regulates tissue invasion and ECM remodeling by macrophages. A, Inverted invasion assay of E0771 tumor cells, either alone or coin-
cubated with TAMs isolated from WT or Dab2 KO tumor-bearing mice. The area of invasion and the mean invasive distance of E0771 cells were evaluated 
by confocal microscopy (n = 3 independent experiments). B, Surface expression of integrins β1, α1, α5, and α6 evaluated by flow cytometry on either WT or 
Dab2 KO BMDMs. The fold changes in mean fluorescence intensity (MFI) relative to WT is reported for each integrin (n = 8 independent experiments). 
C, Expression of integrins β1, α5, and α6 evaluated by Western blot analysis and densitometry on either WT or Dab2 KO BMDMs (left). Actin was used as load-
ing control. Densitometric quantification of Western blot bands reported as fold change over WT samples (right). D, Uptake of FITC-labelled ECM proteins 
by BMDMs is reported as percentage of FITC+ cells measured by flow cytometry at different time points (n = 3 independent experiments). E, Representa-
tive SHG images of collagen fibrils organization in MN-MCA1 WT and Dab2 KO tumors. Scale bar, 50 μm F, Maximum projection intensity through 0–80 μm 
z-stack of SGH signal intensity and peak intensity within MN-MCA1 (WT n = 9 and Dab2 KO n = 8) tumors. Data are presented as mean ± SD. *, P ≤ 0.05;  
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Dab2 or the genes encoding the integrins β1, α5, and α6 
(Supplementary Fig. S5A and S5B; Supplementary Table S1). 
Analogous to TAMs, RAW 264.7 cells support E0771 cell 
invasion when expressing DAB2 (Supplementary Fig.  S5C). 
Tumor cell invasion was reduced only when β1 and α5 
were absent, but was unaffected by integrin α6 modulation 
(Fig.  5A–C). Accordingly, RAW 264.7 clones with the genes 
encoding the β1 and α5 subunits deleted, but not the gene 
encoding α6, displayed a reduced ability to remodel the 
matrix, indicating that α5β1 but not α6β1 integrin dimers 
are required for macrophage-assisted ECM remodeling (Sup-
plementary Fig. S5D). DAB2 expression was similar in all the 
integrin KO clones (Supplementary Fig. S5E), implying that 
the outside-in integrin signaling is not a direct regulator of 
DAB2 expression, at least for the analyzed integrins.
Changes in matrix composition and structure enable inte-
grins to transmit biochemical and mechanical signals to the 
interior of cells and fine-tune cell migration and invasion 
(29). Interestingly, RAW 264.7 WT controls, but not Dab2-
deleted clones, displayed an increased invasive ability in the 
Figure 5.  DAB2+ macrophages favor tumor cell invasion by integrin and ECM interaction. A–C, Inverted in vitro invasion assays of RAW 264.7 CTRL or 
Itgb1 (A), Itga5 (B), and Itga6 KO (C) single-cell–derived clones cocultured with E0771 tumor cells in a Matrigel layer. The area of invasion and the mean 
invasive distance for E0771 were quantified by confocal microscopy (n = 2 independent experiments). D, Transwell invasion assay of RAW 264.7 CTRL 
and Dab2 KO single cell–derived clones using a synthetic matrix (Puramatrix) supplemented with fibronectin (1 μg/mL), laminin (1 μg/mL), collagen I  
(1 μg/mL), collagen IV (10 μg/mL), or vitronectin (1 μg/mL). Cell invasion was evaluated measuring the absorbance at 595 nm of crystal violet stained 
cells (n = 2 independent experiments). E and F,  Western blot analysis for YAP expression on FACS-sorted TAMs from E0771 and MN-MCA1 tumor-bearing 
WT or KO mice (E) or TAMs and MTMs isolated from PyMT mice (F). GAPDH was used as loading control. G, IF performed to evaluate expression of YAP, 
DAB2, and F4/80 on PyMT tumor slices. Scale bar, 10 μm. H, Western blot analysis for DAB2 expression on TAMs isolated from MN-MCA1 tumor–bearing WT, 
Dab2 KO, and Yap–Taz KO mice. I, Quantification of lung metastases in WT (n = 6), Dab2 KO (n = 11), and Yap–Taz KO (n = 7) mice orthotopically injected 
with MN-MCA1 cells. J, Accumulation of different immune populations among CD45+-gated cells in MN-MCA1 tumors from WT (n = 6), Dab2 KO (n = 5), or 
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presence of the ECM proteins that are known to interact 
with DAB2-regulated integrins (i.e., fibronectin, laminin, and 
collagen I and IV), but were unaltered when exposed to vit-
ronectin, which binds αvβ3 integrin, a DAB2-independent 
dimer (Fig. 5D and data not shown). Moreover, the invasive 
ability of RAW 264.7 WT changed according to the ECM pro-
tein concentration, in line with studies on tissue-migrating 
muscle cells (30), but remained unmodified in Dab2-deleted 
clones (Supplementary Fig. S5F).
In response to mechanical inputs due to the high ECM 
stiffness, the mechanotransduction-related cotranscription 
factors YAP and TAZ regulate cell proliferation, survival 
and motility of cancer cells (31, 32), and activation of 
cancer-associated fibroblasts (33). Using a gene set enrich-
ment analysis (GSEA) to correlate Dab2 expression in mac-
rophages with known molecular pathways, we found a 
significant relationship between DAB2- and YAP-related 
signature (31), in addition to the expected correlation with 
CSF1 signaling (Supplementary Fig. S5G). YAP was detect-
able in DAB2-expressing TAMs isolated from E0771, MN-
MCA1, and PyMT tumors but also in MTMs that do not 
express DAB2, demonstrating that YAP expression is inde-
pendent of DAB2 (Fig. 5E and F). Moreover, almost all the 
F4/80+DAB2+ TAMs in the stromal area at the border of the 
tumor mass were also YAP+ (Fig. 5G; 95.7± 2.3% of the total 
F4/80+DAB2+ cells). To investigate whether Dab2 expres-
sion was regulated by mechanotransduction, we generated 
(Yap–Taz)flox/flox;Tie2-Cre+ (Yap–Taz KO) mice. DAB2 expres-
sion was negligible in TAMs sorted from these mice, sug-
gesting that Dab2 transcriptional regulation is controlled 
by the YAP–TAZ complex in vivo (Fig. 5H). Yap–Taz KO mice 
challenged with MN-MCA1 cells phenocopied the Dab2 
KO mice, with a reduced number of lung metastases but 
without any detectable impact on either primary tumor 
growth (data not shown) or leukocyte infiltration (Fig.  5I 
and J). Furthermore, a SHG analysis performed on pri-
mary explants of MN-MCA1 tumors revealed an increased 
collagen fiber density in tumors grown in Yap–Taz KO 
mice compared with WT controls, mirroring the enriched 
ECM network unveiled in Dab2 KO tumors (Supplementary 
Fig. S5H and S5I).
DAB2 Is Expressed in Metastatic Lung and 
Supports Lung Colonization
So far, our results indicated that DAB2+ macrophages are 
essential for matrix remodeling and this process licenses 
tumor cell invasiveness. To explore whether Dab2 expression 
in the hematopoietic compartment affected myeloid cell abil-
ity to reach the metastatic site, we analyzed the myeloid infil-
trate in the lungs of tumor-bearing WT and Dab2 KO mice. 
We found similar percentages of myeloid subpopulations 
(Supplementary Fig.  S6A) Moreover, DAB2-expressing mac-
rophages in MN-MCA1 tumor–bearing mice were localized 
inside the metastatic foci, with a peculiar distribution toward 
the borders (Supplementary Fig. S6B and S6C, left), whereas 
few DAB2-expressing macrophages were present in healthy 
areas of lungs (Supplementary Fig. S6C, right).
Notably, E0771 tumor cells, intravenously injected in either 
WT or Dab2 KO mice, gave rise to lung metastases, but their 
number, mean area, and burden were significantly higher 
in WT mice compared with Dab2 KO mice (Fig. 6A–C), sug-
gesting DAB2 intervention also occurs in distal steps of 
metastasis development. Inflammatory monocytes can assist 
the extravasation of tumor cells from the blood to the lung 
(6). Because DAB2 was detectable at low levels in tumor-infil-
trating monocytes (Fig.  3A), we evaluated their possible aid 
in endothelial transmigration of cancer cells. E0771 tumor 
cells extravasate in a similar manner through an endothelial 
layer in the presence of Ly6C+ monocytes isolated from either 
WT or Dab2 KO–tumor-bearing mice, ruling out this step 
in DAB2-dependent metastatic progression (Supplementary 
Fig. S6D). Moreover, mCherry/Luc E0771 tumor cells, intra-
venously injected in either WT or Dab2 KO mice, seeded 
the lung in similar numbers within the first days of tumor 
challenge (Fig.  6D). Metastases started to be detectable, by 
imaging, 9 days after tumor injection in WT mice, whereas 
no significant luminescence was detectable in Dab2 KO mice 
throughout the observation time. After 28 days, when WT 
mice had to be euthanized, cancer cells increased from about 
104 to 106 per lung, whereas they were barely detectable in 
Dab2 KO mice (Fig. 6D and E), suggesting that Dab2 absence 
could favor tumor cell clearance within the metastatic lung. 
Interestingly, a different CD3+ T-cell frequency was observed 
at the metastatic site, mainly dependent on a reduced percent-
age of CD4+ T cells in Dab2 KO mice; CD8+ T- and NK-cell 
frequencies were unaffected (Supplementary Fig.  S6E). Nev-
ertheless, NK cells in Dab2 KO mice displayed an activated 
phenotype (increased GRZB and CD107a expression along 
with higher expression levels of activatory receptors) that was 
not observed in T lymphocytes (Supplementary Fig.  S6 F-I); 
this landscape was not mirrored at the primary tumor, sug-
gesting that different immune contexts are established at 
the two sites (Supplementary Fig. S2G and data not shown). 
Indeed, in the absence of Dab2 checkpoint immunotherapy 
with anti–PD-1 in MN-MCA1 tumor–bearing mice did not 
alter primary tumor growth but successfully reduced lung 
metastases (Fig. 6F and G). These data suggest that DAB2 is 
not only required for the first steps of metastatic cascade at the 
primary tumors, but could exert a different role in promoting 
cancer cell growth and invasion at the metastatic site. Moreover, 
checkpoint inhibitors synergize with DAB2 absence in con-
trolling metastatic disease.
DAB2+ Macrophage Presence Correlates with 
Worse Prognosis in Patients with Cancer
Breast cancer is a heterogeneous disease, with variability in 
stromal composition and TAM infiltration according to his-
tology [invasive ductal and lobular carcinoma (IDC and ILC, 
respectively)] and molecular subtypes (luminal, HER2-enriched, 
and triple-negative; refs. 2, 34, 35). We assessed the potential 
prognostic role of DAB2 expression in a cohort of 32 patients 
with pure, early-stage ILC tumors who underwent surgery. The 
number of DAB2+ cells with macrophage morphology was 
evaluated in both peritumoral and intratumoral areas (Sup-
plementary Fig. S7A). High DAB2 levels were associated with 
significantly worse 10-year disease-free survival (DFS) for both 
peritumoral and intratumoral areas (Fig.  7A). High levels of 
DAB2 also associated with the presence of lymph node metas-
tases and high tumor cell proliferation index (Ki-67) either in 
peritumoral and intratumoral areas (36) and with vascular 
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invasion in intratumoral area (Supplementary Table S2; Sup-
plementary Fig.  S7B and S7C). Thus, DAB2+ macrophages 
at the tumor site represent a potential prognostic marker for 
tumor progression and metastasis formation in patients with 
primary resected ILC. We then explored the distribution of 
DAB2+ macrophages in another series of luminal ILC cases as 
defined by current guidelines (37). We detected a significantly 
increased number of DAB2+ macrophages, both peritumoral 
and intratumoral, in the luminal B patients compared with 
luminal A (Supplementary Table S3; Fig. 7B). Moreover, focus-
ing only on the luminal patients in The Cancer Genome Atlas 
(TCGA) dataset, DAB2 mRNA expression had a similar negative 
correlation with overall survival also in luminal B IDCs (Supple-
mentary Fig. S7D). We further evaluated the clinical relevance 
of a two-gene signature of DAB2 in association with some genes 
highlighted by the scRNA-seq of mouse samples (Fig. 1B and 
C) and described as protumoral (2, 21, 38). Few ILC luminal B 
cases are present in TCGA cohort; therefore, we focused only on 
Figure 6.  DAB2 expression in MAMs regulates lung colonization. A–C, Quantification of lung micrometastasis number (A), mean area (B), and burden 
(C) at day 20 following E0771 intravenous injection in either WT (n = 9) or Dab2 KO (n = 12) mice. D, Absolute numbers of mCherry+ E0771 cells per lung 
in WT and Dab2 KO mice 1, 2, 3, or 28 days after tumor challenge (n = 3 mice/group). E, Metastasis formation in WT and Dab2 KO mice following mCherry/
Luc E0771-cell intravenous injection, evaluated by bioluminescence imaging. F and G, Primary tumor growth (F) and lung metastases evaluation (G) on 
MN-MCA1 tumor–bearing WT (ISO n = 25, Anti–PD-1 n = 24) or Dab2 KO (ISO n = 18, anti–PD-1 n = 19) mice after immunotherapy with anti–PD-1 or its 
isotopic control. A–D, F, and G, Data are presented as mean ± SD. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 by Student t test.
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patients with IDC. As shown in Fig. 7C–E, high MMP12, CCL7, 
or CCL8 in association with high DAB2 expression strongly cor-
related with a poor clinical outcome, whereas single genes were 
not able to discriminate patients’ survival (MMP12 P = 0.76, 
CCL7 P = 0.45, CCL8 P = 0.45). These data highlight the pres-
ence of shared expression modules across mouse and human 
TMEs. Finally, we assessed the prognostic value of DAB2 
expression in other cancers. A significant inverse correlation in 
survival was observed between high DAB2 mRNA expression 
and poor prognosis in liver and gastric cancer from TCGA 
dataset (Supplementary Fig. S7E). Therefore, we extended our 
analyses to a series of tumor samples from 59 patients affected 
by early-stage gastric cancer who had undergone R0 resection 
(Supplementary Table S4). Also, in this patient group, DAB2+ 
macrophages presented a heterogeneous expression among 
different cases. Patients with high DAB2 expression showed 
a reduction in 3-year cancer-specific survival (CSS) and over-
all survival (OS), either borderline or significant, respectively 
(Supplementary Fig. S7F and S7G).
Discussion
Among tumor-infiltrating immune cells critical for tumor 
progression and metastatic spreading (39), TAMs can sup-
port tumor cell invasion and intravasation at the primary 
site as well as extravasation, seeding, and tumor cell growth 
at the metastatic niche (6, 40–42). Macrophages represent a 
heterogeneous cell population that consists in a continuum 
of different states that cannot be completely recapitulated in 
the bipolar M1–M2 classification. The scRNA-seq of tumor-
infiltrating myeloid cells unveiled that Dab2 deficiency can 
reprogram the tumor microenvironment toward a more 
proinflammatory status in accordance with previous stud-
ies (13, 43). However, we could not uncover any difference 
in M1–M2 polarization among WT and KO mice in either 
TAMs isolated from tumor mass or BMDMs exposed in vitro 
to polarizing signals (data not shown), which prompted us 
to contemplate alternative explanations for the prometastatic 
activity of DAB2. Indeed, we defined a novel Dab2-dependent, 
macrophage-intrinsic pathway that controls cancer dissemi-
nation. Dab2 genetic ablation in macrophages significantly 
affected lung metastasis formation in sarcoma and breast 
cancer models without any overt variation in primary tumor 
growth or dysregulation of antitumor immunity. DAB2 is 
thus a TAM marker associated with macrophage prometa-
static activity. Dab2 upregulation was dependent on CSF1, 
a major determinant of mononuclear phagocyte biology 
(25), which has already been linked to increased tumor 
progression and metastases in PyMT mice (8). Notably, 
CSF1-induced Dab2 upregulation in BM precursors was 
Figure 7.  Prognostic value of DAB2+ TAMs in breast cancers. A, DFS according to peritumoral (low n = 6 vs. high n = 26, ROC-derived optimal cutoffs) 
or intratumoral (low n = 8 vs. high n = 24, ROC-derived optimal cutoffs) DAB2 staining in 32 patients with ILC who had undergone surgery (log-rank P). 
B, Peritumoral and intratumoral DAB2 levels (IHC) in patients with luminal breast cancer (Lum A = 16, Lum B = 14). C–E, Overall survival (OS) according 
to DAB2 + MMP12 expression (C), DAB2 + CCL7 expression (D), and DAB2 + CCL8 expression (E; mRNA, low vs. high) in IDC luminal B breast cancers 
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optimal when cells were maintained under adherence to the 
plastic surface as compared with stimulation in cell suspen-
sion. CSF1 is thus necessary but not sufficient for full gene 
induction. Another significant and in part unexpected find-
ing is that DAB2 deficiency ablates haptotaxis along tissue 
matrix, but not chemotaxis. The mechanistic foundation of 
this dichotomy relies on the physical interaction between 
cells and ECM proteins as prerequisite for ECM remod-
eling and local migration. DAB2+ macrophages invade 3-D 
matrices with movements dependent on ECM protein con-
centration and, likely, matrix stiffness. Dab2-deficient cells 
presented a reduced integrin recycling and a consequent 
higher accumulation of integrins α5, α6, and β1 on their 
surface compared with WT cells. By genetic deletion of single 
integrin chains, we proved the prominent intervention of 
α5β1 heterodimers in DAB2-assisted promotion of tumor 
cell invasion. Interestingly, α5β1 heterodimers preferentially 
bind fibronectin, a typical component of premetastatic niche 
(44, 45). The absolute dependency of DAB2 in TAMs on the 
YAP–TAZ transcription factor complex further argues that 
mechanosensing cues are essential for continuous expres-
sion of the protein within tumor stroma. YAP expression is 
modulated by the substrate stiffness: soft matrices induce 
cytoplasmic retention, whereas stiff matrices cause its nuclear 
transfer and activation (32). To our knowledge, for the first 
time, this study relates DAB2 protein in macrophages to the 
transcriptional YAP–TAZ complex, demonstrating that DAB2 
contributes to downstream events in mechanotransduction, 
acting as a connector between ECM stiffness and integrin 
recycling and functionality. DAB2+ presence in tissue-res-
ident macrophages is limited in healthy tissues; instead, 
DAB2+ macrophages accumulated during tumor progression 
and localized near the invasive front where the stroma stiff-
ness, cellular mechanosignaling, and YAP expression are the 
highest in human breast cancer samples (34). In patients, 
there is a sharp gradient of increasing matrix stiffness from 
the less aggressive breast cancer subtypes, that is, luminal 
A and B, toward the more aggressive basal-like and HER2 
tumors (34). We speculate that less aggressive tumors rely on 
cancer-extrinsic mechanisms (DAB2+ macrophages) to invade 
nearby tissues, whereas the epigenetic rewiring occurring in 
more aggressive variants might render the tumor cells less 
dependent on external aids. Indeed, epigenetically distinct 
subpopulations of breast cancer cells (defined as “trailblazer”) 
able to guide migration of passenger cancer cells were char-
acterized by a seven-gene signature including DAB2, which 
correlated with poor patient outcome in the triple-negative 
breast cancer subtype (46). This might also explain why the 
DAB2 gene is predictive of overall patient survival in luminal 
B immunophenotype (both ILC and IDC histotypes), but not 
in all patients with breast cancer, as instead highlighted for 
gastric and hepatocellular carcinoma. The proof of concept 
that DAB2 protein expression in macrophages might be a bio-
marker for disease stratification will require further validation 
with the simultaneous detection of DAB2 and other known 
macrophage markers (i.e., CD68, CD169) and application to 
different molecular subtypes of breast cancer (luminal, triple 
negative, and HER2+), as well as in tumors with different his-
tologies. The identification of TAM markers is essential for a 
more refined stratification of patients with breast cancer, as 
recently reported for SIGLEC1 and CCL8 expression (2). Nota-
bly, the predictive role of DAB2 as a prognostic marker for poor 
survival in breast cancer is amplified by the association with 
CCL7, a metastasis-promoting cytokine (38), CCL8, which 
was recently pointed out as a marker discriminating TAMs 
in invasive breast cancer tissue specimens (2), and MMP12, a 
macrophage metalloelastase involved in tissue remodeling and 
metastasis promotion (21). In the last few years, several mac-
rophage-targeting drugs have been developed for depletion 
of (i.e., CCR2 or CSF1R antagonists), reprogramming of (i.e., 
PI3Kγ and HDAC inhibitors), or interference with (i.e., argin-
ase 1) effector pathways in macrophages, and clinical trials are 
ongoing (9). However, all these approaches present drawbacks 
due to nonspecific side effects on normal macrophages. More 
importantly, the current cancer drug discovery route is biased 
to ignore the impact of new molecules and treatments for 
metastasis interference. Results from clinical trials in past 
years have not invigorated the development of antimetastatic 
drugs by the pharmaceutical industry (47). We have shown 
here that DAB2 might offer a fully new avenue for anti-
metastatic therapy, wholly disjoined from the primary tumor 
growth. Indeed, DAB2-targeted treatments might interfere 
with the metastatic process at different steps, operating after 
primary tumor resection, to cure hidden or dormant metasta-
ses also in association with immunotherapy. To fully exploit 
this therapeutic combination, however, a deeper understand-
ing of the mechanisms responsible for the efficacy of anti–
PD-1 therapy in controlling hematogenous metastases in 
Dab2-deficient mice, which include a characterization of NK-
cell involvement, will be necessary.
MethoDs
Animal Studies
Eight-week-old C57BL/6 WT mice were purchased from Charles 
River Laboratories Inc. Tie2-Cre (Tek-Cre) and Dab2flox/flox mice were 
originally provided to P.J. Murray (St. Jude Children’s Research 
Hospital, Memphis, TN) from J.A. Cooper (Fred Hutchinson Can-
cer Center, Seattle, WA) and were cross-bred to generate Dab2 
KO mice. LySM-Cre mice were a gift from P. Scapini (University 
of Verona, Verona, Italy). MMTV-PyMT mice on the C57BL/6 
background were kindly provided by M.P. Colombo (Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan, Italy). MMTV-PyMT, 
Dab2flox/flox, Tie2-Cre+ mice were generated in house by crossing three 
strains and maintained by intercross. Yapflox/floxTazflox/flox mice were 
kindly provided by S. Piccolo (University of Padua, Padua, Italy) and 
were cross-bred with Tie2-Cre mice to generate Yap–Taz KO mice. 
OT-1 TCR-transgenic mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J) and 
CD45.1+ congenic mice (B6.SJL-PtrcaPepcb/BoyJ) were purchased 
from Jackson Laboratories. All mice were maintained under specific 
pathogen-free conditions in the animal facility of the University of 
Verona. Animal experiments were performed according to national 
(protocol number 12722 approved by the Ministerial Decree Num-
ber 14/2012-B of January 18, 2012 and protocol number BR15/08 
approved by the Ministerial Decree Number 925/2015-PR of August 
28, 2015) and European laws and regulations. All animal experi-
ments were approved by Verona University Ethical Committee and 
conducted according to the guidelines of Federation of European 
Laboratory Animal Science Association (FELASA). All animal experi-
ments were in accordance with the Amsterdam Protocol on animal 
protection and welfare: mice were monitored daily and euthanized 
when displaying excessive discomfort.
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Cell Cultures
Murine E0771 breast cancer cells derived from C57BL/6 mice 
(CH3 BioSystems, #94A001) were cultured in RPMI 1640 (Euro-
clone). Murine MN-MCA1 fibrosarcoma cell line (gift from A. Sica, 
Istituto Humanitas, Milan, Italy), RAW264.7 macrophage cell line 
(ATCC TIB-71), and SVEC4-10 endothelial cell line (gift from A. 
Viola, Istituto di Ricerca Pediatrica, Padua, Italy; originally obtained 
from ATCC CRL-2181) were cultured in DMEM (Euroclone). All 
media were supplemented with 10% heat-inactivated FBS (Superior, 
Merck), 20 μmol/L β-Mercaptoethanol (Sigma-Aldrich), 2 mmol/L 
l-glutamine, 10 mmol/L HEPES, 150 U/mL streptomycin, 200 U/mL 
penicillin/streptomycin (all from Euroclone). Cell lines were thawed 
from primary stocks maintained under liquid nitrogen and cultured 
for a maximum of 1 month (E0771, RAW264.7, and SVEC4-10) or for 
few passages (MN-MCA1), during which time all experiments were 
performed. The cultures were maintained at 37°C in 5% CO2-humidi-
fied atmosphere and regularly tested for Mycoplasma using MycoAlert 
LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich).
Patients with Breast Cancer
To explore the prognosis (in terms of DFS) according to DAB2 
expression, tumor samples with clinical annotations from a series 
of 32 patients affected by pure invasive lobular carcinoma (Supple-
mentary Table S2) and surgically treated at the University Hospital 
of Verona, were collected. In addition, with the aim to evaluate the 
distribution of DAB2 according to tumor cell proliferation (by the 
IHC assessment of Ki-67 antigen), a series of luminal ILC was col-
lected (n = 30; Supplementary Table S3). A database for individual 
data and information was appropriately fulfilled. The study was 
approved by the local Ethics Committee (Prot. CESC n° 24163, 
May 20, 2014).
Patients with Gastric Cancer
The potential prognostic role of DAB2 in gastric cancer was evalu-
ated in terms of CSS and OS. Data and samples from 59 patients 
affected by gastric cancer who underwent surgery at the University 
Hospital of Verona (Verona, Italy) were collected (Supplementary 
Table S4). Tumor samples were available in tissue microarrays with 
tumor cores of each considered case and obtained from the inner part 
of the tumors. The study was approved by the local Ethics Committee 
(Prot. CESC n° 19147 November 28, 2011).
Spontaneous and Experimental Metastases Assays
For spontaneous metastasis formation, breast cancer (E0771) and 
fibrosarcoma (MN-MCA1) cell lines were orthotopically injected into 
the mammary fat pad (5 × 105 cells/mouse) and into the left quadriceps 
of mice (105 cells/mouse) respectively. Tumor growth was monitored 
every 2 days using a digital caliper. The greatest longitudinal diameter 
(length) and the greatest transverse diameter (width) were determined 
and tumor volume was calculated by the modified ellipsoidal formula: 
tumor volume = 1/2 (length × width2). In the case of E0771-injected 
mice, tumors were resected at 800 mm3 of volume, to favor distal dis-
semination. For experimental metastasis formation, eight-week-old 
WT or Dab2 KO females were injected with 4 × 105 E0771 cells into the 
tail vein. Mice were euthanized 20 days after tumor cell injection and 
lungs were analyzed for metastasis formation. 106 E0771-mCherry/
Luc cells were intravenously injected in WT or Dab2 KO mice to fol-
low metastasis seeding and growth at the metastatic site using in vivo 
bioluminescence imaging every week (IVIS Spectrum optical imager). 
For spontaneous tumorigenesis and metastasis studies, MMTV-PyMT 
female mice carrying the specific oncogenes were examined weekly for 
mammary tumors to define tumor incidence. Thirteen weeks after the 
appearance of the first tumor, mice were euthanized and lungs were 
analyzed for metastasis formation.
Anti–PD-1 Immunotherapy
The effect of anti–PD-1 immunotherapy was investigated in 
C57BL/6J mice, WT or Dab2 KO, after an orthotopic challenge with 
105 MN-MCA1 cells. Tumor-bearing mice with established tumor 
masses were treated using 4 iterative intraperitoneal administra-
tions of anti–PD-1 mAb (clone RMP1-14; InVivoMAb) or isotype Ab 
(clone 2A3) every 2 days. The complete treatment consists of 1 mg of 
Ab. MN-MCA1–bearing mice were euthanized 25 days after tumor 
challenge for metastases evaluation.
CRISPR/Cas9 Gene Editing
For each DNA target coding sequence (Dab2, Itgβ1, Itgα5, Itgα6), 
three sgRNAs with the highest scores on target and lowest num-
bers of off-targets were chosen using the MIT CRISPR design 
tool (http://crispr.mit.edu/) and cloned in pSpCas9(BB)-2A-GFP 
(PX458) vector (Addgene), which also encoded a reporter gene 
(GFP) and Cas9 protein. Control digestion and Sanger sequenc-
ing were performed to evaluate the success of cloning. Plasmid 
transfection in RAW264.7 cells was performed with K2 reagent 
(Biontex). After two days, cells were collected, enriched for GFP 
using a FACS Aria II Flow Cytometer Cell Sorter (BD Biosciences), 
and cultured as single cell–derived clones. Clones were screened 
by protein (flow cytometry and Western blot analyses) and genetic 
(Sanger sequencing) analysis.
scRNA-seq
Tumors pooled from 3 PyMT-WT and 3 PyMT-Dab2 KO mice were 
digested as reported above and myeloid cells were FACS-sorted as 
CD45+ lineage (CD3, CD19, NK1.1) negative cells. Sorted cell suspen-
sion (10,000 cells, about 650 cells/μL) was loaded on a GemCode Single 
Cell Instrument (10x Genomics Chromium System) to generate single-
cell GEMs (Gel bead-in-EMulsion). scRNA-seq libraries were prepared 
using GemCode Single Cell 3′ Gel Bead and Library Kit v2 (10x Genom-
ics). Sequencing was performed using an Illumina NextSeq500 with 26 
bases for Read1 and 98 bases for Read2. Demultiplexing and alignment 
to the Mouse mm10 genome were done with 10x Cell Ranger v3.0.2. 
Output for the two samples were then merged using Cell Ranger Aggr, 
where WT reads were downsampled to account for its slightly higher 
read count compared with Dab2 KO. The resulting combined gene × cell 
UMI count dataset was used for downstream analysis utilizing the func-
tions of the Seurat v3 R package (see Supplementary Information). Raw 
sequencing data have been deposited in the Gene Expression Omnibus 
(GEO) under accession number GSE152674.
Invasion Assays
In vitro invasion assays were performed using Matrigel and 8-μm 
pore transwells (both from Corning Inc.). BMDMs or RAW264.7 
cells were resuspendend in 2% FBS growth medium and seeded on 
top of the polymerized Matrigel, whereas 20% FBS growth medium 
was added in the well as cell chemoattractant. For BMDMs, CSF1 
(100 ng/mL) was added both in the underneath well and on top 
of the Matrigel. After 4 days, Matrigel was removed, and invading 
cells were fixed, stained with crystal violet, and eluted with a solu-
tion containing 50% ethanol and 0.1% acetic acid. Absorbance was 
measured at 595 nm using a microplate reader (VersaMax, Molecular 
Devices). In the invasion assay with tumor cells, BMDMs were left in 
culture for 3 days to remodel the matrix and killed with puromycin 
(5 μg/mL) for 48 hours. After several washes, E0771 cells were seeded 
on top of the Matrigel in 2% FBS culture medium, while 20% FBS 
medium was added in the underneath well. Breast cancer cell inva-
sion ability was evaluated after 24 hours by crystal violet elution 
and absorbance measurement. To study the correlation between 
DAB2, integrins, and EMC components in the metastatic process, 
Puramatrix synthetic matrix (Corning Inc.) was mixed with different 
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amounts of fibronectin, laminin (Thermo Fisher Scientific), vitro-
nectin, collagen I (Corning Inc.), and collagen IV (BD Biosciences), 
coated on 8-μm pore transwells. Invading ability was assessed by 
crystal violet elution after 72 hours.
Inverted Invasion Assay
Macrophage ability to remodel the ECM and to guide invasion 
of cancer cells was tested by in vitro inverted invasion assays. Breast 
cancer cells (E0771) and TAMs or RAW264.7 cells were labeled with 
CellVue (Thermo Fisher Scientific) and PKH dyes (Sigma-Aldrich), 
respectively, and mixed with Matrigel (Corning Inc.) on chambered 
cell culture slides (Thermo Fisher Scientific). After the polymeriza-
tion, a layer of Matrigel mixed with 5% Collagen Type I−FITC conju-
gate was added on the top. Once polymerized, Matrigel was covered 
with complete medium, creating a chemotactic gradient. After 72 
hours, 6 random fields for each condition were imaged at fixed inter-
vals (10 μm) starting at the fluorescent layer and in a direction toward 
the chemotactic gradient using the z-stack setting of Leica TCS SP5 
confocal microscope. To evaluate tumor cell invasion ability, distance 
travelled and invaded areas were quantified using ImageJ software.
SHG Imaging
To evaluate possible differences in ECM organization within 
tumors derived from WT, Dab2 KO, and Yap–Taz KO mice, we took 
advantage of SHG to image fibrillar, cross-linked collagen in tissues. 
SHG signal was acquired through an 80-μm z-stack in fixed tumor 
samples, using a 25× NA 1.05 water-immersion objective (Olym-
pus XLPLN25XWMP2) on a custom-built microscope, described in 
detail elsewhere (48). A 800-nm laser wavelength/395 nm ± 25 nm 
emission wavelength was used to collect SHG signal from collagen I 
fibers. Images were then analyzed for signal intensity of each single 
z-step (8-μm steps) or maximum projection intensity of z-stack, using 
ImageJ software.
In Vitro Dab2 Induction
CD11b+ cells were immunomagnetically sorted from tumor-free 
and MN-MCA1 tumor–bearing mice and cultured for 24 hours in 
the presence of serum-free growth media supplemented with CSF1 
(100 ng/mL) or E0771 supernatant. Alternatively, cells were grown in 
coculture with previously irradiated (8,000 rad) E0771 cells. To assess 
whether CSF1 has a direct effect on Dab2 gene expression, TAMs 
isolated from MN-MCA1 tumor-bearing mice were cultured with 
CSF1 (100 ng/mL) for 24 hours. To understand if Dab2 expression is 
modulated by adhesion, CD11b+ cells were isolated from tumor-free 
mice and cultured for 6 hours in adhesion on a plastic surface or in 
suspension. In both conditions, CSF1 or E0771 supernatant were 
added to the serum-free growth media. Samples were harvested for 
RNA isolation. Dab2 expression was analyzed by real-time PCR and 
normalized on unstimulated cells.
Statistical Analyses
Student t test (parametric groups) and Wilcoxon–Mann–Whitney 
test (nonparametric groups) were used to determine statistical signifi-
cance of differences between two treatment groups, and ANOVA test 
was used in the case of multiple comparisons. Growth curves were 
analyzed with repeated measures two-way ANOVA using the SAS 
system. Survival analysis was performed using the Kaplan–Meier sur-
vival analysis (log-rank) method. Values were considered significant at 
P ≤ 0.05. Values are reported as mean ± SE or SD. All analyses were 
performed using Graph Pad Prism (version 8.4.2).
Statistical Analyses for Patients
Descriptive statistics was adopted. Follow-up was analyzed and 
reported according to Shuster and colleagues (49). DAB2 expression 
data were obtained from the IHC staining on patient biopsies. The 
ROC analysis was applied to the DAB2 continuous score to dichoto-
mize the obtained values according to DFS for patients with ILC. 
To correlate DAB2 expression with clinicopathologic data, Pearson 
χ2 test or Fisher exact test were used, depending on sample size. The 
presence of lymph node metastases, tumor cell proliferation (Ki-67 
expression), and vascular invasion (V.I.) inside the primary breast 
tumor were considered as characteristics of interest.
DFS, CSS, and OS curves were elaborated using the Kaplan–
Meier method, and significance was calculated with the log-rank 
test. P values were considered significant when ≤0.05. The SPSS 
18.0, R 2.6.1, and MedCalc 14.2.1 statistical programs were used 
for all analyses.
For complete experimental details and reagents, please see Sup-
plementary Methods.
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